These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25126373)

  • 1. The health and economic effects of counterfeit drugs.
    Blackstone EA; Fuhr JP; Pociask S
    Am Health Drug Benefits; 2014 Jun; 7(4):216-24. PubMed ID: 25126373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example.
    Sugita M; Miyakawa M
    Environ Health Prev Med; 2010 Jul; 15(4):244-51. PubMed ID: 21432552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Counterfeit medicines--Japan and the world].
    Sato D
    Yakugaku Zasshi; 2014; 134(2):213-22. PubMed ID: 24492225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counterfeit drugs and medical devices in developing countries.
    Glass BD
    Res Rep Trop Med; 2014; 5():11-22. PubMed ID: 32669888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
    Nsimba SE
    East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-counterfeit activities of pharmaceutical companies in Japan: for patient safety].
    Shofuda K; Aragane K; Igari Y; Matsumoto K; Ito K
    Yakugaku Zasshi; 2014; 134(2):203-11. PubMed ID: 24492224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Counterfeit drugs as a gobal threat to health].
    Golocorbin Kon S; Mikov M
    Med Pregl; 2011; 64(5-6):285-90. PubMed ID: 21789919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in counterfeit drugs and pharmaceuticals before and during COVID-19 pandemic.
    Ziavrou KS; Noguera S; Boumba VA
    Forensic Sci Int; 2022 Sep; 338():111382. PubMed ID: 35882074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the problem of counterfeit medications in the United Kingdom.
    Jackson G; Patel S; Khan S
    Int J Clin Pract; 2012 Mar; 66(3):241-50. PubMed ID: 22070229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain.
    Cuomo RE; Mackey TK
    BMJ Open; 2014 Dec; 4(12):e006657. PubMed ID: 25468507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I (Don't) want to consume counterfeit medicines: exploratory study on the antecedents of consumer attitudes toward counterfeit medicines.
    Ofori-Parku SS; Park SE
    BMC Public Health; 2022 Jun; 22(1):1094. PubMed ID: 35650557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment.
    Mackey TK; Liang BA; York P; Kubic T
    Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):59-67. PubMed ID: 25897059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism.
    Mackey TK; Liang BA
    BMC Med; 2013 Oct; 11():233. PubMed ID: 24228892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economics of counterfeit Avastin: a geospatial and statistical analysis of demographic correlates to FDA warning letters.
    Cuomo RE; Mackey TK; Stigler P
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):748-56. PubMed ID: 26016718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counterfeit pharmaceuticals: current status and future projections.
    Wertheimer AI; Chaney NM; Santella T
    J Am Pharm Assoc (2003); 2003; 43(6):710-7; quiz 717-8. PubMed ID: 14717268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries.
    Tadeg H; Berhane Y
    East Afr J Public Health; 2012 Jun; 9(2):85-9. PubMed ID: 23139963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States.
    Michael White C
    J Am Pharm Assoc (2003); 2021; 61(1):e93-e98. PubMed ID: 32471767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication safety issue brief. Counterfeit drug prevention and identification.
    ; ;
    Hosp Health Netw; 2005 Aug; 79(8):29-30. PubMed ID: 16247941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.